Blau Farmacêutica (BLAU3) Q4 2025 earnings summary

Executive summary

• Strategic divestment from Prothya in 2025 reinforced capital structure, enabling record investments in biotechnology and production capacity, and a return to a net cash position.

• Achieved Anvisa certification for the first locally produced biosimilar monoclonal antibody (pembrolizumab), marking a major milestone.

• Despite a 3% revenue decline to BRL 1.7 billion, operational efficiency gains drove margin improvements and a 39% net income increase to BRL 297 million.

• Record shareholder remuneration included BRL 400 million in stock bonuses and BRL 182 million in dividends and interest on equity.

• Largest organic investment in company history, with CAPEX reaching BRL 419 million.

Financial highlights

• Net income reached BRL 297 million, up 39% year-over-year, with net margin rising to 13.9%.

• Revenue was BRL 1.7 billion, a 3% decrease, mainly due to bid delays and product mix changes.

• Gross margin improved by 260 bps to 40–40.1%, and EBITDA margin increased by 50 bps to 22.8–23%.

• Recurring EBITDA was BRL 389–391 million; recurring net income grew 7% to BRL 236 million.

• Launches contributed BRL 127 million (7.5% of revenue), up 18% year-over-year.

Outlook and guidance

• Expecting revenue growth and margin improvement in 2026, driven by new bid wins, expanded production capacity, and robust launch pipeline.

• Four new production lines and increased packaging capacity to be delivered in 2026.

• Focus on biosimilars and monoclonal antibodies as key growth drivers, leveraging upcoming patent expirations.

• CapEx projected at BRL 600 million for 2026, with similar levels for 2027, mainly for clinical trials and Pernambuco expansion.

• Anticipate less volatility in public sector revenue and continued international expansion, especially in Latin America.